{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:38:19Z","timestamp":1793414299174,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001675","name":"International Brain Research Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001675","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007928","name":"Perelman School of Medicine, University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000104","name":"National Aeronautics and Space Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.neulet.2020.135432","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T11:05:55Z","timestamp":1602932755000},"page":"135432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Does chronic systemic injection of the DREADD agonists clozapine-N-oxide or Compound 21 change behavior relevant to locomotion, exploration, anxiety, and depression in male non-DREADD-expressing mice?"],"prefix":"10.1016","volume":"739","author":[{"given":"Fionya H.","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella L.","family":"Spears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4184-482X","authenticated-orcid":false,"given":"Kyung J.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6476-5385","authenticated-orcid":false,"given":"Amelia J.","family":"Eisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghee","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2020.135432_bib0005","doi-asserted-by":"crossref","first-page":"9268","DOI":"10.1523\/JNEUROSCI.1333-16.2016","article-title":"Resolving behavioral output via Chemogenetic designer receptors exclusively activated by designer drugs","volume":"36","author":"Burnett","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2020.135432_bib0010","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.neuron.2016.01.040","article-title":"DREADDs for neuroscientists","volume":"89","author":"Roth","year":"2016","journal-title":"Neuron."},{"key":"10.1016\/j.neulet.2020.135432_bib0015","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1073\/pnas.0700293104","article-title":"Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand","volume":"104","author":"Armbruster","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neulet.2020.135432_bib0020","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1038\/s41598-019-41088-2","article-title":"Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice","volume":"9","author":"Jendryka","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neulet.2020.135432_bib0025","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0219-16.2016","article-title":"Clozapine N-Oxide administration produces behavioral effects in long\u2013evans rats: implications for designing DREADD experiments","author":"MacLaren","year":"2016","journal-title":"eNeuro"},{"key":"10.1016\/j.neulet.2020.135432_bib0030","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1038\/s41598-018-22116-z","article-title":"The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice","volume":"8","author":"Manvich","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neulet.2020.135432_bib0035","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1126\/science.aan2475","article-title":"Chemogenetics revealed: DREADD occupancy and activation via converted clozapine","volume":"357","author":"Gomez","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.neulet.2020.135432_bib0040","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/oxfordjournals.schbul.a033333","article-title":"Management of the adverse effects of clozapine","volume":"24","author":"Young","year":"1998","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neulet.2020.135432_bib0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0014-2999(97)01234-X","article-title":"Dopamine D receptor and anxiety: behavioural profiles of clozapine, L-745, 870 and L-741, 742 in the mouse plus-maze","volume":"335","author":"Cao","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2020.135432_bib0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0278-5846(01)00280-9","article-title":"Effect of low doses of clozapine on behaviour of isolated and group-housed male mice in the elevated plus-maze test","volume":"26","author":"Manzaneque","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neulet.2020.135432_bib0055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0091-3057(90)90125-2","article-title":"Anxiolytic potential of sulpiride, clozapine and derivatives in the open-field test","volume":"36","author":"Bruhwyler","year":"1990","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neulet.2020.135432_bib0060","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0091-3057(97)00461-9","article-title":"Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs","volume":"59","author":"Rex","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neulet.2020.135432_bib0065","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.pbb.2008.04.014","article-title":"Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: contrast with haloperidol and chlordiazepoxide","volume":"90","author":"Mead","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neulet.2020.135432_bib0070","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fnbeh.2018.00173","article-title":"Behavioral effects of acute systemic low-dose clozapine in wild-type rats: implications for the use of DREADDs in behavioral neuroscience","volume":"12","author":"Ilg","year":"2018","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neulet.2020.135432_bib0075","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1038\/s41467-019-12236-z","article-title":"High-potency ligands for DREADD imaging and activation in rodents and monkeys","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neulet.2020.135432_bib0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1021\/acsptsci.8b00012","article-title":"DREADD agonist 21 is an effective agonist for muscarinic-based DREADDs in vitro and in vivo","volume":"1","author":"Thompson","year":"2018","journal-title":"ACS Pharmacol Transl Sci."},{"key":"10.1016\/j.neulet.2020.135432_bib0085","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1523\/JNEUROSCI.0537-18.2018","article-title":"Chemogenetic manipulations of ventral tegmental area dopamine neurons reveal multifaceted roles in cocaine abuse","volume":"39","author":"Mahler","year":"2019","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2020.135432_bib0090","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41591-018-0002-1","article-title":"Stimulation of entorhinal cortex-dentate gyrus circuitry is antidepressive","volume":"24","author":"Yun","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.neulet.2020.135432_bib0095","series-title":"The Principle of Humane Experimental Technique","author":"Russell","year":"1959"},{"key":"10.1016\/j.neulet.2020.135432_bib0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/FBP.0b013e3282f62cb2","article-title":"Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice","volume":"19","author":"Bruins Slot","year":"2008","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neulet.2020.135432_bib0105","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3389\/fnins.2019.00702","article-title":"Chemogenetic modulation of orexin neurons reverses changes in anxiety and locomotor activity in the A53T mouse model of parkinson\u2019s disease","volume":"13","author":"Stanojlovic","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neulet.2020.135432_bib0110","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.celrep.2016.05.034","article-title":"Recombinase-dependent mouse lines for chemogenetic activation of genetically defined cell types","volume":"15","author":"Sciolino","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.neulet.2020.135432_bib0115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1017\/S1461145708009085","article-title":"Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation","volume":"12","author":"Gray","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neulet.2020.135432_bib0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/gene.1078","article-title":"A CamKIIalpha iCre BAC allows brain-specific gene inactivation","volume":"31","author":"Casanova","year":"2001","journal-title":"Genesis."},{"key":"10.1016\/j.neulet.2020.135432_bib0125","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.cmet.2013.09.009","article-title":"Rapid versus delayed stimulation of feeding by the endogenously released AgRP neuron mediators GABA, NPY, and AgRP","volume":"18","author":"Krashes","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.neulet.2020.135432_bib0130","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0219-16.2016","article-title":"Clozapine N-oxide administration produces behavioral effects in Long--evans rats: implications for designing DREADD experiments","volume":"3","author":"MacLaren","year":"2016","journal-title":"Eneuro"},{"key":"10.1016\/j.neulet.2020.135432_bib0135","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1172\/JCI92008","article-title":"Arcuate neuropeptide Y inhibits sympathetic nerve activity via multiple neuropathways","volume":"127","author":"Shi","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neulet.2020.135432_bib0140","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1172\/JCI66432","article-title":"Chronic activation of a designer Gq-coupled receptor improves \u03b2 cell function","volume":"123","author":"Jain","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neulet.2020.135432_bib0145","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/dvg.22949","article-title":"Cre-dependent DREADD (Designer receptors exclusively activated by designer drugs) mice","volume":"54","author":"Zhu","year":"2016","journal-title":"Genesis"},{"key":"10.1016\/j.neulet.2020.135432_bib0150","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s40478-019-0814-3","article-title":"Chronic nigral neuromodulation aggravates behavioral deficits and synaptic changes in an \u03b1-synuclein based rat model for Parkinson\u2019s disease","volume":"7","author":"Torre-Muruzabal","year":"2019","journal-title":"Acta Neuropathol. Commun."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394020307023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394020307023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T20:36:36Z","timestamp":1759610196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394020307023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":30,"alternative-id":["S0304394020307023"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2020.135432","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.17.100909","asserted-by":"object"}]},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does chronic systemic injection of the DREADD agonists clozapine-N-oxide or Compound 21 change behavior relevant to locomotion, exploration, anxiety, and depression in male non-DREADD-expressing mice?","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2020.135432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"135432"}}